Bristol-Myers, Merck win FDA review for Reblozyl label expansion
· seekingalpha.com
Bristol-Myers Squibb (BMY) has won FDA review for a marketing application seeking a label expansion for its Merck (MRK)-partnered anemia drug Reblozyl. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...